Editas Medicine (EDIT) Equity Average (2016 - 2025)

Editas Medicine (EDIT) has 10 years of Equity Average data on file, last reported at $20.4 million in Q4 2025.

• Equity Average for Q4 2025 came in at $20.4 million, down 86.85% year-over-year; the trailing twelve-month figure through Dec 2025 was $20.4 million (down 86.85% YoY), and the FY2025 annual result was $80.8 million, down 66.58% from the prior year.
• Equity Average grew to $20.4 million in Q4 2025 per EDIT's latest filing, from $16.3 million in the prior quarter.
• Over five years, Equity Average peaked at $625.7 million in Q2 2021 and troughed at $16.3 million in Q3 2025.
• A 5-year average of $335.7 million and a median of $356.7 million in 2023 frame the typical range for Equity Average.
• The sharpest annual moves came in 2021 and 2025: Equity Average jumped 107.56% in 2021, then tumbled 91.99% in 2025.
• A 5-year view of Equity Average shows it stood at $570.2 million in 2021, then plunged by 32.01% to $387.7 million in 2022, then retreated by 8.49% to $354.8 million in 2023, then tumbled by 56.32% to $155.0 million in 2024, then tumbled by 86.85% to $20.4 million in 2025.
• Business Quant data shows EDIT's Equity Average at $20.4 million in Q4 2025, $16.3 million in Q3 2025, and $40.8 million in Q2 2025.